Efficacy of Polyethylene Glycol Loxenatide in Combination with Basal Insulin in Patients with Type 2 Diabetes Mellitus: A Retrospective Real-World Study
Authors:
Open Access
- 11 April 2025
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (8) , 1581-1592
Abstract
Introduction Patients with type 2 diabetes mellitus (T2DM) who cannot achieve normal glycosylated hemoglobin (HbA1c) levels are sometimes given the combined therapeutic regimen of polyethylene glycol loxenatide (PEG-Loxe) + basal insulin. The aim of this study was to investigate the efficacy and safety of PEG-Loxe combined with basal insulin in patients with T2DM. Methods This retrospective, real-world study included patients with T2DM aged ≥ 18 years for whom basal insulin therapy was ineffective, whose HbA1c levels were between 7.0% and 11.0%, and who were on either continued basal insulin dose adjustment or who had received PEG-Loxe + basal insulin combined therapy for at least 24 weeks. The primary endpoint was change in HbA1c level after 24 weeks treatment. Secondary endpoints included HbA1c achievement target rate, change in fasting plasma glucose and body weight, respectively, and change in HbA1c stratified by sex, age, disease duration, and baseline HbA1c level. Results Overall, 307 patients were identified. After propensity score matching, 44 patients each were included in the basal insulin and PEG-Loxe + basal insulin group. After 24 weeks, a significant difference in Hb1Ac reduction between the groups (P = 0.003) was observed. Also, patients treated with PEG-Loxe + basal insulin combined therapy experienced greater body weight reduction compared those treated with basal insulin only (intergroup difference: − 3.2 kg; 95% confidence interval [95% CI] − 5.4, − 1.0]; P = 0.005). There was a significant intergroup difference in weight reduction in patients with body mass index ≥ 28 kg/m2 (− 8.4 kg; 95% CI − 13.9, − 3.0; P = 0.004). HbA1c levels in female patients aged < 65 years with HbA1c ≥ 8.5% and with a disease duration ≥ 10 years were significantly different between the two treatment groups (P < 0.005). Hypoglycemic events occurred in 10.4% of patients treated with PEG-Loxe + basal insulin with no cases of level 3 hypoglycemia. Conclusion PEG-Loxe + basal insulin combined therapy was safe and effective in patients with T2DM who did not achieve optimal glycemic control with insulin therapy alone. Trial Registration ClinicalTrials.gov identifier: ChiCTR2400086699.Keywords
Funding Information
- China International Medical Foundation (Z-2017-26-1902-5)
- Jiangsu Hansoh Pharmaceutical Co Ltd
This publication has 30 references indexed in Scilit:
- Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin TherapyDiabetes Technology & Therapeutics, 2015
- Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetesThe Journal of Clinical Pharmacology, 2014
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetesThe Lancet Diabetes & Endocrinology, 2014
- Effect of gender on treatment outcomes in type 2 diabetes mellitusDiabetes Research and Clinical Practice, 2013
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 DiabetesAnnals of Internal Medicine, 2011
- Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and MetforminDiabetes Care, 2010
- Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient settingClinical Therapeutics, 2009
- Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes MellitusEndocrine Practice, 2008
- Cardiovascular risk in the spectrum of type 2 diabetes mellitus2006
- Impaired β-Cell Function in Human Aging: Response to Nicotinic Acid-Induced Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism, 2006